Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated by Analysts at Truist Financial

Truist Financial started coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research report released on Tuesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $56.00 target price on the stock.

Other equities research analysts have also issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, September 8th. Robert W. Baird boosted their target price on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the company an “outperform” rating in a research report on Tuesday, September 9th. Raymond James Financial restated an “outperform” rating and set a $63.00 target price (up from $56.00) on shares of Dianthus Therapeutics in a research report on Tuesday, September 9th. Finally, Guggenheim boosted their target price on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, September 9th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Dianthus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $60.88.

Dianthus Therapeutics Price Performance

Shares of DNTH opened at $35.54 on Tuesday. The firm has a market capitalization of $1.14 billion, a PE ratio of -10.94 and a beta of 1.58. Dianthus Therapeutics has a 1-year low of $13.36 and a 1-year high of $40.16. The company’s fifty day moving average price is $30.09 and its 200-day moving average price is $22.92.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). The company had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. As a group, research analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of the company’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total value of $700,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 16.56% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. RA Capital Management L.P. raised its position in shares of Dianthus Therapeutics by 53.6% during the 1st quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company’s stock worth $52,003,000 after purchasing an additional 1,000,333 shares during the last quarter. Moody Aldrich Partners LLC acquired a new position in shares of Dianthus Therapeutics during the 1st quarter worth about $1,349,000. Walleye Capital LLC raised its position in shares of Dianthus Therapeutics by 29.0% during the 1st quarter. Walleye Capital LLC now owns 106,931 shares of the company’s stock worth $1,940,000 after purchasing an additional 24,041 shares during the last quarter. Vestal Point Capital LP raised its position in shares of Dianthus Therapeutics by 58.1% during the 1st quarter. Vestal Point Capital LP now owns 1,700,069 shares of the company’s stock worth $30,839,000 after purchasing an additional 625,069 shares during the last quarter. Finally, Nuveen LLC acquired a new position in shares of Dianthus Therapeutics during the 1st quarter worth about $1,168,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.